With more than 20 years experience of antimicrobial research in major pharma companies, David was recently the scientific leader in two biotech businesses (Piramed & RiboTargets) that achieved successful exit for investors.
Neill has worked for over 18 years within academia and the pharmaceutical industry. He has a proven track record of research as evidenced by publications in a variety of scientific and medical research areas predominantly infectious disease, oncology, cardiovascular disease, and drug safety assessment.
Drs. Mike Darsley & Philip Bedford (ex-Acambis; vaccine clinical development); Dr Martin Comberbach (ex-SKB Biologicals; vaccine manufacture; Prof. Vance Fowler (clinician, S. aureus); Dr J Mond (ex-CSO Biosynexus, clinician, S. aureus); Prof Mark Wilcox (clinician, C. difficile).